CTOs on the Move

Connectyx

www.connectyx.com

 
Connectyx is a development-stage biomedical company focusing on novel treatments for rare diseases. In November, the Company announced it is changing its name to Curative Biotechnology, Inc. and has applied for the name change and a trading symbol (CURB) with the Financial Industry Regulatory Authority, Inc., which should take effect in the first quarter of 2021. Connectyx is focused on therapies with potentially accelerated development paths as a result of either the disease, the nature of the therapeutic itself, or the stage of clinical development. At the heart of the Company is a product development engine that rests on our ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.connectyx.com
  • 1825 NorthWest Corporate Boulevard Suite 110
    Boca Raton, FL USA 33431
  • Phone: 800.526.8006

Executives

Name Title Contact Details
Ronald Bordens
 Executive Vice President of Technical Operations and Manufacturing Profile

Similar Companies

SIGA Technologies

SIGA Technologies is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Soundbite Medical Solutions

SoundBite Medical is a medical devices company that began operations in May 2015, with its R&D facilities in Sherbrooke and commercialization headquarters in Montreal, Quebec. The Company is developing and commercializing proprietary wire-based device and generator console that delivers safe shockwave energy within the cardiovascular system to treat chronic total occlusions.

Plenum Scientific Research

Plenum Scientific Research, Inc is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Surface Logix

Surface Logix, Inc. is a Brighton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Casma Therapeutics

New discoveries are revealing the fundamental role of autophagy and lysosomal flux in maintaining cellular health. Furthermore, it is now appreciated that inadequate or aberrant autophagy contributes to a wide range of diseases. We are focused on boosting autophagy – pioneering novel therapeutic strategies to address unmet medical needs. We are creating a new target set for drug discovery and development, and advancing innovative paradigms to treat a broad set of illnesses that are either neglected or inadequately addressed today. Our growing team is driven to transform fundamental discoveries on autophagy into promising therapeutic medicines.